The Phase II NADIM II trial (NCT03838159) was designed to explore neoadjuvant nivolumab plus chemotherapy versus chemotherapy alone in patients with locally advanced and potentially resectable non-small cell lung cancer (NSCLC). Atocha Romero, PharmD, PhD, Hospital Universitario Puerta de Hierro, Madrid, Spain, talks on an analysis of circulating tumor DNA (ctDNA) from the pre-treatment plasma samples of patients enrolled in the NADIM II trial. Baseline ctDNA was detected in 52 of 54 pre-treatment samples and were significantly associated with tumor size. Pre-treatment ctDNA levels were significantly associated with progression-free survival (PFS) and overall-survival (OS). Overall, baseline ctDNA evidently identified patients at high risk of progression or death and may therefore be utilized to tailor subsequent treatment. Additionally, ctDNA was significantly associated with tumor size. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
